The Legacy of Great Science: The Work of Nobel Laureate Gertrude Elion Lives On
Level 5 - mechanism / opinion, no new human data
Historical narrative and biographical profile with no primary empirical data (grade by design analogy).
OpenAlex W2163211067 · doi:10.1634/theoncologist.11-9-961
What was done
This paper presents a historical and biographical profile examining the scientific career and legacy of Nobel laureate Gertrude Elion. It details her collaborative work in rational drug design alongside George Hitchings, her laboratory's synthesis of purine antimetabolite compounds, and the translation of those compounds through academic, clinical, and industrial collaborations leading up to the regulatory approval of nelarabine for rare T-cell leukemias and lymphomas.
What was found
The abstract reports no quantitative empirical data. It traces the therapeutic lineage of compounds developed by or originating from Elion's laboratory, including 6-mercaptopurine and thioguanine for childhood leukemia, azathioprine for organ transplantation, acyclovir for herpes, allopurinol for gout, pyrimethamine for malaria, trimethoprim, zidovudine (AZT) for HIV/AIDS, and the precursor compound leading to nelarabine.
Why it matters
The paper outlines the foundational impact of rational purine antimetabolite design across oncology, virology, and immunology, documenting how basic chemistry and sustained cross-sector collaboration established enduring drug discovery frameworks.
Limits
This is a historical narrative and retrospective profile rather than a clinical trial or empirical study. The abstract contains no primary quantitative outcomes, comparator groups, or statistical evaluations.
Cited by
- supports Gertrude Elion and George Hitchings won a Nobel Prize for developing nucleoside and nucleotide analogs as anticancer and antiviral drugs at Research Triangle Park.